The European Medicines Agency�s Committee for Medicinal Products for Human Use (CHMP) gave a positive view by recommending approval of Bristol-Myers Squibb�s $BMY opdivo (nivolumab) for the treatment of patients with relapsed/refractory classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin (Seattle Genetics' $SGEN ADCETRIS).Clinical trial demonstrated Opdivo delivered an objective response rate (ORR) of 66% in these patients. A final decision from the European Commission typically takes about 60 days.